• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病发生和进展的分子途径。

Molecular pathways of nonalcoholic fatty liver disease development and progression.

机构信息

Hospital Provincial del Centenario, Facultad de Ciencias Médicas, Servicio de Gastroenterología y Hepatología, Universidad Nacional de Rosario, Rosario, Argentina.

Instituto de Fisiología Experimental (IFISE-CONICET), Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 570, 2000, Rosario, Argentina.

出版信息

Cell Mol Life Sci. 2019 Jan;76(1):99-128. doi: 10.1007/s00018-018-2947-0. Epub 2018 Oct 20.

DOI:10.1007/s00018-018-2947-0
PMID:30343320
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11105781/
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a main hepatic manifestation of metabolic syndrome. It represents a wide spectrum of histopathological abnormalities ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) with or without fibrosis and, eventually, cirrhosis and hepatocellular carcinoma. While hepatic simple steatosis seems to be a rather benign manifestation of hepatic triglyceride accumulation, the buildup of highly toxic free fatty acids associated with insulin resistance-induced massive free fatty acid mobilization from adipose tissue and the increased de novo hepatic fatty acid synthesis from glucose acts as the "first hit" for NAFLD development. NAFLD progression seems to involve the occurrence of "parallel, multiple-hit" injuries, such as oxidative stress-induced mitochondrial dysfunction, endoplasmic reticulum stress, endotoxin-induced, TLR4-dependent release of inflammatory cytokines, and iron overload, among many others. These deleterious factors are responsible for the triggering of a number of signaling cascades leading to inflammation, cell death, and fibrosis, the hallmarks of NASH. This review is aimed at integrating the overwhelming progress made in the characterization of the physiopathological mechanisms of NAFLD at a molecular level, to better understand the factor influencing the initiation and progression of the disease.

摘要

非酒精性脂肪性肝病(NAFLD)是代谢综合征的主要肝脏表现。它代表了一系列广泛的组织病理学异常,从单纯性脂肪变性到非酒精性脂肪性肝炎(NASH),伴有或不伴有纤维化,最终发展为肝硬化和肝细胞癌。虽然肝单纯性脂肪变性似乎是肝甘油三酯积聚的一种良性表现,但与胰岛素抵抗诱导的大量脂肪从脂肪组织动员以及葡萄糖诱导的新的肝脂肪酸合成相关的高毒性游离脂肪酸的积累是 NAFLD 发展的“第一击”。NAFLD 的进展似乎涉及“平行、多次打击”损伤的发生,如氧化应激诱导的线粒体功能障碍、内质网应激、内毒素诱导的 TLR4 依赖性炎症细胞因子释放和铁过载等。这些有害因素负责触发许多信号级联反应,导致炎症、细胞死亡和纤维化,这是非酒精性脂肪性肝炎的特征。这篇综述旨在整合在分子水平上对 NAFLD 生理病理机制的描述性进展,以更好地理解影响疾病起始和进展的因素。

相似文献

1
Molecular pathways of nonalcoholic fatty liver disease development and progression.非酒精性脂肪性肝病发生和进展的分子途径。
Cell Mol Life Sci. 2019 Jan;76(1):99-128. doi: 10.1007/s00018-018-2947-0. Epub 2018 Oct 20.
2
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.非酒精性脂肪性肝病与肝纤维化分期。
Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18.
3
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.非酒精性脂肪性肝病:从非酒精性脂肪性肝病到非酒精性脂肪性肝炎的进展中的基本发病机制。
Transplantation. 2019 Jan;103(1):e1-e13. doi: 10.1097/TP.0000000000002480.
4
New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎中脂毒性的新方面。
Int J Mol Sci. 2018 Jul 13;19(7):2034. doi: 10.3390/ijms19072034.
5
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease.氧化应激在非酒精性脂肪性肝病发病机制中的作用。
Oxid Med Cell Longev. 2018 Jun 11;2018:9547613. doi: 10.1155/2018/9547613. eCollection 2018.
6
Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病
Adv Exp Med Biol. 2017;960:443-467. doi: 10.1007/978-3-319-48382-5_19.
7
Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD.肝脏脂质代谢中的脂肪酸和葡萄糖传感器:对非酒精性脂肪性肝病的影响
Semin Liver Dis. 2015 Aug;35(3):250-61. doi: 10.1055/s-0035-1562945. Epub 2015 Sep 17.
8
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.与健康正常体重个体相比,不同程度非酒精性脂肪性肝病患者的肝转录组特征。
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. doi: 10.1152/ajpgi.00358.2018. Epub 2019 Jan 17.
9
Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.非酒精性脂肪性肝炎的发病机制:营养过剩的代谢并发症如何导致脂毒性和促炎脂肪性肝病。
Adv Exp Med Biol. 2018;1061:19-44. doi: 10.1007/978-981-10-8684-7_3.
10
Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.利用动物模型研究非酒精性脂肪性肝炎相关的肝细胞癌。
Oncotarget. 2016 Jul 5;7(27):42762-42776. doi: 10.18632/oncotarget.8641.

引用本文的文献

1
Divergent Hepatic and Adipose Tissue Effects of Kupffer Cell Depletion in a Male Rat Model of Metabolic-Associated Steatohepatitis.在雄性大鼠代谢相关脂肪性肝炎模型中,库普弗细胞耗竭对肝脏和脂肪组织的不同影响
Biology (Basel). 2025 Aug 15;14(8):1058. doi: 10.3390/biology14081058.
2
Induction of Autophagy as a Therapeutic Breakthrough for NAFLD: Current Evidence and Perspectives.诱导自噬作为非酒精性脂肪性肝病的治疗突破:当前证据与展望
Biology (Basel). 2025 Aug 4;14(8):989. doi: 10.3390/biology14080989.
3
The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.细胞因子在代谢功能障碍相关脂肪性肝病中的有趣作用:一篇叙述性综述
Curr Obes Rep. 2025 Aug 12;14(1):65. doi: 10.1007/s13679-025-00657-5.
4
AISI and MASLD: a nonlinear association in U.S. adults (NHANES 2017-2020).美国成年人中的美国印第安人标准指数(AISI)与代谢功能障碍相关脂肪性肝病(MASLD):一种非线性关联(2017 - 2020年美国国家健康与营养检查调查)
BMC Gastroenterol. 2025 Aug 11;25(1):572. doi: 10.1186/s12876-025-04210-5.
5
Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity.包含索拉非尼和常春藤皂苷元衍生物的共组装纳米颗粒用于增强抗肝纤维化活性
Int J Nanomedicine. 2025 Jul 18;20:9135-9153. doi: 10.2147/IJN.S512005. eCollection 2025.
6
Ferroptosis as a potential therapeutic target for obesity-related metabolic diseases.铁死亡作为肥胖相关代谢性疾病的潜在治疗靶点。
Front Pharmacol. 2025 Jul 4;16:1581632. doi: 10.3389/fphar.2025.1581632. eCollection 2025.
7
Recent advances in anterior pituitary hormones and metabolic-associated fatty liver disease.垂体前叶激素与代谢相关脂肪性肝病的最新进展
Front Endocrinol (Lausanne). 2025 Jul 4;16:1600559. doi: 10.3389/fendo.2025.1600559. eCollection 2025.
8
Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives.非酒精性脂肪性肝病的药物治疗:当代治疗方法与未来展望
Int J Mol Sci. 2025 Jul 7;26(13):6518. doi: 10.3390/ijms26136518.
9
INHIBITION OF THE PROSTAGLANDIN-DEGRADING ENZYME 15-PGDH AMELIORATES MASH-ASSOCIATED APOPTOSIS AND FIBROSIS IN MICE.抑制前列腺素降解酶15-羟基前列腺素脱氢酶可改善小鼠中与马什相关的细胞凋亡和纤维化。
Cells. 2025 Jun 27;14(13):987. doi: 10.3390/cells14130987.
10
Global, regional and national burden of Metabolic dysfunction-associated steatotic liver disease in adolescents and adults aged 15-49 years from 1990 to 2021: results from the 2021 Global Burden of Disease study.1990年至2021年15至49岁青少年和成年人中代谢功能障碍相关脂肪性肝病的全球、区域和国家负担:2021年全球疾病负担研究结果
Front Med (Lausanne). 2025 Jun 25;12:1568211. doi: 10.3389/fmed.2025.1568211. eCollection 2025.

本文引用的文献

1
Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view.综述文章:非酒精性脂肪性肝病背景下的药物性肝损伤——病理生理学和临床综合观点。
Aliment Pharmacol Ther. 2018 Nov;48(9):892-913. doi: 10.1111/apt.14952. Epub 2018 Sep 7.
2
The hedgehog pathway in nonalcoholic fatty liver disease.刺猬通路与非酒精性脂肪性肝病。
Crit Rev Biochem Mol Biol. 2018 Jun;53(3):264-278. doi: 10.1080/10409238.2018.1448752. Epub 2018 Mar 20.
3
Formation of p62-positive inclusion body is associated with macrophage polarization in non-alcoholic fatty liver disease.p62阳性包涵体的形成与非酒精性脂肪性肝病中的巨噬细胞极化有关。
Hepatol Res. 2018 Aug;48(9):757-767. doi: 10.1111/hepr.13071. Epub 2018 Apr 10.
4
Adiponectin: A potential therapeutic target for metabolic syndrome.脂联素:代谢综合征的潜在治疗靶点。
Cytokine Growth Factor Rev. 2018 Feb;39:151-158. doi: 10.1016/j.cytogfr.2018.01.004. Epub 2018 Jan 12.
5
Matrix metalloproteinases and liver fibrosis (translational aspects).基质金属蛋白酶与肝纤维化(转化医学相关)。
Matrix Biol. 2018 Aug;68-69:463-473. doi: 10.1016/j.matbio.2017.12.012. Epub 2017 Dec 28.
6
Insights into the Hexose Liver Metabolism-Glucose versus Fructose.葡萄糖与果糖的肝脏代谢研究进展
Nutrients. 2017 Sep 16;9(9):1026. doi: 10.3390/nu9091026.
7
Cytosolic lipolysis and lipophagy: two sides of the same coin.细胞质脂肪分解和脂肪自噬:同一枚硬币的两面。
Nat Rev Mol Cell Biol. 2017 Nov;18(11):671-684. doi: 10.1038/nrm.2017.76. Epub 2017 Aug 30.
8
Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity.脂肪因子:2型糖尿病和肥胖症血管功能障碍的潜在治疗靶点
J Diabetes Res. 2017;2017:8095926. doi: 10.1155/2017/8095926. Epub 2017 Feb 13.
9
Fructose and NAFLD: The Multifaceted Aspects of  Fructose Metabolism.果糖与非酒精性脂肪性肝病:果糖代谢的多方面问题
Nutrients. 2017 Mar 3;9(3):230. doi: 10.3390/nu9030230.
10
Genetic predisposition in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中的遗传易感性。
Clin Mol Hepatol. 2017 Mar;23(1):1-12. doi: 10.3350/cmh.2016.0109. Epub 2017 Mar 9.